Comparing the current results to its competitors, Petros Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 12.47 %, recorded in the same quarter.
Petros Pharmaceuticals inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 5.99 %
Petros Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The ACNU Rx-to-OTC licensing marketplace is expanding, with potential competition from companies offering proprietary, licensable technology. Idea Evolver is identified as a technology firm providing support to sponsors in ACNU switch platforms and developing platforms that may be licensed to other companies. Currently, no FDA-approved ACNU therapeutics have transitioned from prescription to over-the-counter status, and no established conceptor technology platform exists for FDA-approved commercialization or licensable use, resulting in an absence of a competitive landscape for licensable ACNU Rx-to-OTC switch technologies. The Company's proprietary technology platform is in early development and seeks to differentiate itself by incorporating elements such as Artificial Intelligence to validate patient identification factors, in contrast to most existing platforms that rely primarily on questionnaire-based models. The platform is also being developed to integrate electronic health records and population longitudinal data.
Portage Biotech Inc.'s business model involves the identification and development of innovative therapeutics and healthcare solutions, leveraging a unique portfolio of biotechnology companies and their technologies.
Urogen Pharma Ltd is a pharmaceutical company that specializes in developing and commercializing innovative therapies for urological and oncological conditions. Their business model revolves around conducting extensive research and development to create novel therapies, obtaining necessary regulatory approvals, and strategically partnering with healthcare providers and other stakeholders to market and distribute their products globally. By focusing on addressing unmet medical needs in the urology field, Urogen Pharma aims to improve patient outcomes and establish a strong presence in the market.
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Verastem Inc is a biopharmaceutical company that focuses on discovering and developing medicines to treat cancer by targeting the underlying biology of the disease. They employ a research-driven business model to identify novel therapeutic candidates, evaluate their potential through preclinical and clinical trials, and bring them to market with the goal of improving patient outcomes. Verastem emphasizes innovation, precision medicine, and strategic collaborations to advance their pipeline of cancer therapeutics.
Sources:
Petros Pharmaceuticals inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Petros Pharmaceuticals inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
